A single dose sub-unit vaccine protects against pneumonic plague.
about
An alternative approach to combination vaccines: intradermal administration of isolated components for control of anthrax, botulism, plague and staphylococcal toxic shockLong-term observation of subunit vaccine F1-rV270 against Yersinia pestis in miceEfficacy and safety of a modified vaccinia Ankara (MVA) vectored plague vaccine in mice.Antigen engineering can play a critical role in the protective immunity elicited by Yersinia pestis DNA vaccines.Human immune response to a plague vaccine comprising recombinant F1 and V antigens.Mucosally delivered Salmonella typhi expressing the Yersinia pestis F1 antigen elicits mucosal and systemic immunity early in life and primes the neonatal immune system for a vigorous anamnestic response to parenteral F1 boost.Remote monitoring of the progression of primary pneumonic plague in Brown Norway rats in high-capacity, high-containment housing.Efficacy of primate humoral passive transfer in a murine model of pneumonic plague is mouse strain-dependent.LcrV delivered via type III secretion system of live attenuated Yersinia pseudotuberculosis enhances immunogenicity against pneumonic plague.Yersinia pestis (plague) vaccines.Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis.Plague vaccine research and development.Administration of antibody to the lung protects mice against pneumonic plague.The ABC transporter protein OppA provides protection against experimental Yersinia pestis infection.Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge.Development of a vaccinia virus based reservoir-targeted vaccine against Yersinia pestisAdvanced Development of the rF1V and rBV A/B Vaccines: Progress and Challenges.Delayed inflammatory response to primary pneumonic plague occurs in both outbred and inbred micePilot Study on the Use of DNA Priming Immunization to Enhance Y. pestis LcrV-Specific B Cell Responses Elicited by a Recombinant LcrV Protein Vaccine.Bioinformatics, genomics and evolution of non-flagellar type-III secretion systems: a Darwinian perspective.Relative immunogenicity and protection potential of candidate Yersinia Pestis antigens against lethal mucosal plague challenge in Balb/C mice.Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plagueProtective immunity against plague.Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection.Adenovirus-mediated delivery of an anti-V antigen monoclonal antibody protects mice against a lethal Yersinia pestis challenge.Pneumonic plague pathogenesis and immunity in Brown Norway rats.Dual-function antibodies to Yersinia pestis LcrV required for pulmonary clearance of plagueRational considerations about development of live attenuated Yersinia pestis vaccinesThe role of immune correlates and surrogate markers in the development of vaccines and immunotherapies for plague.Plague: Infections of Companion Animals and Opportunities for Intervention.Plague Vaccines: Status and Future.Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis.Immunogenicity of a Yersinia pestis vaccine antigen monomerized by circular permutationIpaD localizes to the tip of the type III secretion system needle of Shigella flexneri
P2860
Q27486899-F00647C0-EF6A-4ADD-8F93-C6E5185DAA81Q33613422-24F7977C-C8FE-479A-961C-9AD2F8600EE7Q33635050-7780BC9C-9AF4-4B3D-9F84-7F7EFAC2CFE2Q33698142-6AFB72C4-8C20-4A92-8111-CF50D1E4A7C1Q33788286-A19DAB18-8A0E-4402-915F-7DA6019BFF02Q33824782-60910254-EE36-4462-99B3-0255DBDEB23DQ33934619-7197C8B5-A22B-4160-85D2-C7360EAEC1E0Q33942640-46CE2011-39F7-4D12-9F0C-1EF2B695DA3EQ34298699-177B5F79-0B31-4F40-B71E-32D12AF84A76Q34324211-66BB42D7-E2B8-4803-A415-3E0F0479F467Q34334406-AC91D60A-8F68-4D7F-939D-BC32C23DDECAQ34384011-C9BCA8F1-D4DB-4EE2-A24E-239DC3376FD7Q34601788-BD522BB4-CD8B-4B72-89B3-8F8C63554131Q34681213-66A69039-3FD6-4148-8C09-B6D9E66AECAEQ34819434-EFBD13A0-0D31-4255-8C41-EA42E5961BAFQ35090599-DD88444D-944F-47F6-B614-3CB89C5AFF04Q35418294-7939B246-3F78-4653-B057-2EE4F56AE0FEQ35689282-2E2C7782-E85C-44C8-9690-16D36443F112Q35826610-CB77D53F-6347-453D-946C-63DEF9725AD2Q36088671-6B9A0930-47D1-49B5-892F-42DF8F98DB05Q36528895-C6C76085-1E73-4DC0-A295-D619A93D4A07Q36974485-2F30E4D6-4790-4E3C-B16C-076F13F95F4EQ36984069-D9089E00-5035-41F8-AEE8-E1C5306EC63FQ37066697-EAA404F3-4154-4192-9868-9093128AB389Q37145022-A4233BA7-1B7C-494D-8EFB-9ED761315671Q37150791-64381E4C-A92A-4C6B-8557-9FDF7FD4A5BBQ37450884-F902BDC9-E9B5-4F92-87B9-A25E6474A30DQ37688618-58275F4C-BD18-42A4-B97A-898A5D8CA25AQ38589273-7FA6D0E4-5B9B-43C9-B0DD-4381A9593D9AQ38612499-080C7877-C30D-4226-B50C-F076A91A3E29Q38813137-CDCF2A6D-A38B-4E14-A488-8A157BECA6C7Q39741669-1D3D9600-67C0-4306-825D-8C9CB3A7CC5CQ41057955-7273A871-8718-402A-BED3-AA345E4C154BQ41856079-46B994C3-5455-4769-A90B-0BCE88E84B80
P2860
A single dose sub-unit vaccine protects against pneumonic plague.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
A single dose sub-unit vaccine protects against pneumonic plague.
@en
type
label
A single dose sub-unit vaccine protects against pneumonic plague.
@en
prefLabel
A single dose sub-unit vaccine protects against pneumonic plague.
@en
P2093
P1433
P1476
A single dose sub-unit vaccine protects against pneumonic plague.
@en
P2093
P304
P356
10.1016/S0264-410X(00)00159-6
P407
P577
2000-10-01T00:00:00Z